BACKGROUND: Apolipoprotein E (ApoE) is associated with some diseases with cognitive function defect. AIMS: The purpose of this study was to examine the influence of ApoE on poststroke depression (PSD) risk and to define objective markers for diagnosis. METHODS: The cognitive function, serum ApoE, and peripheral mononuclear blood cell ApoE mRNA expression of patients with PSD were compared to age-matched control patients with stroke and healthy volunteers. Sixty-seven patients with stroke were selected according to the cerebral infarction diagnosis standard of the Fourth National Cerebrovascular Disease Conference and divided into a PSD group (28 patients, 43-76 years old) or a control stroke group (39 patients, 43-78 years old) using the Hamilton Rating Scale for Depression, and compared to 40 healthy volunteers (42-78 years old). Cognitive function was evaluated by analysis of event-related potentials (ERPs), while expression of ApoE mRNA was determined by quantitative reverse transcription-polymerase chain reaction and serum ApoE by ELISA. RESULTS: The latencies of ERP components N2 and P3 were prolonged, and the P3 amplitude was lower in the PSD group compared to the control stroke group and healthy controls (p<0.01). There were no significant group differences in N1 and P2 latencies (all p>0.05). The latency of N2 was positively correlated to the P3 latency in the PSD group (p<0.05). No associations were detected between P3 amplitude, expression of ApoE mRNA, and serum ApoE in the PSD group (all p>0.05). The ERP results indicated that patients with PSD were significantly slower at identifying a target stimulus, suggesting deficits in perception and/or cognitive processing. Peripheral expression of ApoE mRNA was lower in the PSD group than the control stroke group (p<0.701) while serum ApoE was higher than in the control stroke group (p<0.05), possibly reflecting a feedback reduction in expression. CONCLUSION: We suggest that aberrant serum ApoE together with abnormalities in some ERP components may be useful markers for assessment of PSD risk and clinical diagnosis.
BACKGROUND:Apolipoprotein E (ApoE) is associated with some diseases with cognitive function defect. AIMS: The purpose of this study was to examine the influence of ApoE on poststroke depression (PSD) risk and to define objective markers for diagnosis. METHODS: The cognitive function, serum ApoE, and peripheral mononuclear blood cell ApoE mRNA expression of patients with PSD were compared to age-matched control patients with stroke and healthy volunteers. Sixty-seven patients with stroke were selected according to the cerebral infarction diagnosis standard of the Fourth National Cerebrovascular Disease Conference and divided into a PSD group (28 patients, 43-76 years old) or a control stroke group (39 patients, 43-78 years old) using the Hamilton Rating Scale for Depression, and compared to 40 healthy volunteers (42-78 years old). Cognitive function was evaluated by analysis of event-related potentials (ERPs), while expression of ApoE mRNA was determined by quantitative reverse transcription-polymerase chain reaction and serum ApoE by ELISA. RESULTS: The latencies of ERP components N2 and P3 were prolonged, and the P3 amplitude was lower in the PSD group compared to the control stroke group and healthy controls (p<0.01). There were no significant group differences in N1 and P2 latencies (all p>0.05). The latency of N2 was positively correlated to the P3 latency in the PSD group (p<0.05). No associations were detected between P3 amplitude, expression of ApoE mRNA, and serum ApoE in the PSD group (all p>0.05). The ERP results indicated that patients with PSD were significantly slower at identifying a target stimulus, suggesting deficits in perception and/or cognitive processing. Peripheral expression of ApoE mRNA was lower in the PSD group than the control stroke group (p<0.701) while serum ApoE was higher than in the control stroke group (p<0.05), possibly reflecting a feedback reduction in expression. CONCLUSION: We suggest that aberrant serum ApoE together with abnormalities in some ERP components may be useful markers for assessment of PSD risk and clinical diagnosis.
Authors: Maria Aparecida Camargos Bicalho; Fausto Aloísio Pimenta; Luciana Bastos-Rodrigues; Érika de Oliveira Hansen; Samara Canguçu Neves; Marina Melo; Daniela Valadão Rosa; Renan Pedra de Souza; Débora Marques de Miranda; Edgar Nunes de Moraes; Marco Aurélio Romano-Silva; Luiz De Marco Journal: Int J Geriatr Psychiatry Date: 2012-08-17 Impact factor: 3.485
Authors: Gareth J McKay; Giuliana Silvestri; Usha Chakravarthy; Shilpa Dasari; Lars G Fritsche; Bernhard H Weber; Claudia N Keilhauer; Michael L Klein; Peter J Francis; Caroline C Klaver; Johannes R Vingerling; Lintje Ho; Paulus T D V De Jong; Michael Dean; Julie Sawitzke; Paul N Baird; Robyn H Guymer; Dwight Stambolian; Anton Orlin; Johanna M Seddon; Inga Peter; Alan F Wright; Caroline Hayward; Andrew J Lotery; Sarah Ennis; Michael B Gorin; Daniel E Weeks; Chia-Ling Kuo; Aroon D Hingorani; Reecha Sofat; Valentina Cipriani; Anand Swaroop; Mohammad Othman; Atsuhiro Kanda; Wei Chen; Goncalo R Abecasis; John R Yates; Andrew R Webster; Anthony T Moore; Johan H Seland; Mati Rahu; Gisele Soubrane; Laura Tomazzoli; Fotis Topouzis; Jesus Vioque; Ian S Young; Astrid E Fletcher; Chris C Patterson Journal: Am J Epidemiol Date: 2011-04-15 Impact factor: 4.897
Authors: P Hollingworth; R Sweet; R Sims; D Harold; G Russo; R Abraham; A Stretton; N Jones; A Gerrish; J Chapman; D Ivanov; V Moskvina; S Lovestone; P Priotsi; M Lupton; C Brayne; M Gill; B Lawlor; A Lynch; D Craig; B McGuinness; J Johnston; C Holmes; G Livingston; N J Bass; H Gurling; A McQuillin; P Holmans; L Jones; B Devlin; L Klei; M M Barmada; F Y Demirci; S T DeKosky; O L Lopez; P Passmore; M J Owen; M C O'Donovan; R Mayeux; M I Kamboh; J Williams Journal: Mol Psychiatry Date: 2011-10-18 Impact factor: 15.992
Authors: Eva Kitzlerová; Zdeněk Fišar; Petra Lelková; Roman Jirák; Martina Zvěřová; Jana Hroudová; Ada Manukyan; Pavel Martásek; Jiří Raboch Journal: Med Sci Monit Date: 2018-04-28
Authors: Manish D Paranjpe; Xueqi Chen; Min Liu; Ishan Paranjpe; Jeffrey P Leal; Rongfu Wang; Martin G Pomper; Dean F Wong; Tammie L S Benzinger; Yun Zhou Journal: Neuroimage Clin Date: 2019-03-28 Impact factor: 4.881